Press Releases

 

Statement on Our Commitment to Diversity and Equality

Statement on COVID-19

As we continue to monitor COVID-19 developments, at Neurocrine Biosciences we are committed to the safety, health and well-being of our patients, customers and employees. To healthcare providers and their patients with tardive dyskinesia or Parkinson’s disease, we do not anticipate any disruption in our ability to supply INGREZZA® (valbenazine) or ONGENTYS® (opicapone). Be assured, we remain focused on our mission to discover, develop and deliver important medicines to treat patients with neurological, endocrine, and psychiatric disorders.


DateTitle 
11/30/21
SAN DIEGO , Nov. 30, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Jude Onyia , Ph.D., has joined the company's executive management team as Chief Scientific Officer. Dr. Onyia , a scientist with more than 25 years of experience in the pharmaceutical
11/22/21
Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023 Sosei Heptares receives US$100 million upfront, ongoing R&D funding, and up to US$2.6 billion in
11/9/21
SAN DIEGO , Nov. 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:     Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Financial Officer will present at
11/1/21
INGREZZA® (valbenazine) Third Quarter 2021 Net Product Sales of $287 Million with Approximately 52,000 Total Prescriptions SAN DIEGO , Nov. 1, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2021 .
11/1/21
SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Neurocrine Biosciences , Inc. (Nasdaq: NBIX) today announced that it presented new data from its movement disorder program for tardive dyskinesia (TD) at the 2021 Psych Congress scientific meeting being held October 29–November 1, 2021.
10/16/21
SAN DIEGO , Oct. 16, 2021 /PRNewswire/ -- Neurocrine Biosciences , Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement disorder treatments for Parkinson's disease and tardive dyskinesia (TD) at the American Neurological Association (ANA) 2021 Virtual Annual
10/11/21
Conference Call and Webcast Scheduled for Monday, November 1 SAN DIEGO , Oct. 11, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter 2021 financial results after the Nasdaq market closes on Monday, November 1, 2021 .
10/8/21
- The Sculpture "Monumental Moments™ - The Hug" Revealed at NYC's Lincoln Center on October 7 During Mental Illness Awareness Week and Ahead of World Mental Health Day Accompanied by Boston-Based Me2/Orchestra - Monumental Moments Community Platform and Charitable Initiative Continues to Encourage
9/10/21
- Long-term Data from KINECT 4 Study Found that Long-Term Tardive Dyskinesia (TD) Symptom Reductions were Achieved with Once-Daily INGREZZA - New Pooled Analysis of Two Phase 3 Studies Found Treatment with ONGENTYS as an Add-On to Levodopa/Carbidopa Decreased the Frequency of Nighttime Awakenings
9/2/21
SAN DIEGO , Sept. 2, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following virtual investor conferences:     Kevin Gorman , Chief Executive Officer, will present at the Morgan Stanley 19 th Annual
8/5/21
- Top-Line Readout of Clinical Study Results Anticipated by the End of 2021 - Initiating Expanded Enrollment to New Participants in Open-Label Extension Study KINECT-HD2 SAN DIEGO , Aug. 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), in collaboration with the Huntington Study
8/3/21
INGREZZA® (valbenazine) Second Quarter 2021 Net Product Sales of $265 Million with Approximately 48,900 Total Prescriptions Phase 3 Registrational Program of Valbenazine for the Treatment of Chorea Associated with Huntington Disease Fully Enrolled with Top-Line Data Expected by Year-End SAN DIEGO ,
7/22/21
Patients Overall Satisfied with Telehealth Care Received During the Pandemic but also Worry Things Will Be Missed on Telehealth SAN DIEGO, July 22, 2021 – A new Neurocrine Biosciences, Inc. (Nasdaq: NBIX) survey conducted by The Harris Poll found that 80% of Americans will always prefer in-person
7/19/21
Conference Call and Webcast Scheduled for Tuesday, August 3 SAN DIEGO , July 19, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, August 3, 2021 .
7/8/21
SAN DIEGO , July 8, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Kyle Gano , Chief Business Development and Strategy Officer, will participate in a neuropsychology-focused panel discussion at the William Blair Biotech Focus Conference at 12:00 p.m.
6/1/21
SAN DIEGO , June 1, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42 nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, June 8, 2021 . Kevin Gorman , Chief Executive Officer, will present at the conference.
5/11/21
SAN DIEGO , May 11, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021 . Matt Abernethy , Chief Financial Officer, and Eiry Roberts, Chief Medical Officer, will
5/5/21
INGREZZA® (valbenazine) First Quarter 2021 Net Product Sales of $230 Million with Approximately 43,300 TRx Initiated Pediatric Phase III Registrational Program of Crinecerfont for the Treatment of Classic Congenital Adrenal Hyperplasia Initiated Phase II Study of NBI-827104 in Essential Tremor SAN
5/4/21
SAN DIEGO , May 4, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday May 11, 2021 . Kevin Gorman , Chief Executive Officer, will present at the conference.
5/3/21
- Mental Health Advocacy Community Recognizes and Over 40 States Declare First Week of May (2-8) Tardive Dyskinesia Awareness Week to Raise Awareness of this Burdensome and Often Misunderstood Condition - Recent Survey Results Show That More Than Half (60%) of People Living With Diagnosed or
4/16/21
SAN DIEGO , April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercialization of Gilead's
4/14/21
Conference Call and Webcast Scheduled for Wednesday, May 5 SAN DIEGO , April 14, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter 2021 financial results after the Nasdaq market closes on Wednesday, May 5, 2021 .
4/8/21
SAN DIEGO , April 8, 2021 /PRNewswire/ -- Neurocrine Biosciences , Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology's (AAN) 73rd Annual Meeting being held virtually from April 17–22, 2021.
3/25/21
SAN DIEGO , March 25, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3 rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021 . Eiry Roberts, Chief Medical Officer, and Kyle Gano , Chief Business Development and Strategy Officer, will
3/20/21
- Additional Positive Data from Phase II CAHlibrate Study - Real-World Data Highlight Impact of CAH in Adult and Pediatric Patients SAN DIEGO , March 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present additional positive data from its Phase II
3/9/21
SAN DIEGO , March 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31 st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021 . Matt Abernethy , Chief Financial Officer, will present at the conference.
3/2/21
- Negative Outcome on Primary Endpoint Measured by the Change from Baseline on the Positive and Negative Syndrome Scale/Negative Symptom Factor Score (PANSS NSFS) - Positive Outcome on Cognitive Assessment Secondary Endpoints Support Potential Further Clinical Development of Luvadaxistat - No New
2/23/21
SAN DIEGO , Feb. 23, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 41 st Annual Health Care Conference at 1:30 p.m. Eastern Time on Tuesday Mar. 2, 2021 . Kevin Gorman , Chief Executive Officer, will present at the conference.
2/4/21
Total Annual Revenues in 2020 Grew 33% to Over $1 Billion INGREZZA® (valbenazine) Full Year 2020 Net Product Sales and TRx Both Grew 32% to $993 Million and Approximately 175,700 TRx, Respectively Mitsubishi Tanabe Pharma Corporation (MTPC) Reports Successful Top-Line Results for Asia-Based
1/20/21
Conference Call and Webcast Scheduled for Thursday, February 4 SAN DIEGO , Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq market closes on Thursday, Feb. 4, 2021 .
1/8/21
INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales and Inventory Adjusted Net Product Sales of Approximately $240 Million and $258 Million, Respectively INGREZZA® (valbenazine) Preliminary Full-Year 2020 Net Product Sales and TRx Both Grew 32% to Approximately $993 Million and
1/4/21
SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 39 th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan. 11, 2021 . Kevin Gorman , Chief Executive Officer, will present at the conference.